EverSource Wealth Advisors LLC Sells 61 Shares of Insulet Co. (NASDAQ:PODD)

EverSource Wealth Advisors LLC lessened its holdings in shares of Insulet Co. (NASDAQ:PODD) by 21.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 223 shares of the medical instruments supplier’s stock after selling 61 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Insulet were worth $43,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of PODD. Sunbelt Securities Inc. purchased a new stake in shares of Insulet during the first quarter valued at approximately $29,000. International Assets Investment Management LLC purchased a new stake in shares of Insulet during the 2nd quarter valued at $32,000. UMB Bank n.a. raised its stake in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the period. Jones Financial Companies Lllp bought a new stake in shares of Insulet during the 4th quarter worth $40,000. Finally, CVA Family Office LLC grew its position in Insulet by 138.1% during the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after buying an additional 145 shares during the period.

Insulet Stock Down 1.4 %

Shares of PODD opened at $232.03 on Friday. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $243.98. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The stock has a 50 day simple moving average of $206.81 and a two-hundred day simple moving average of $190.42. The firm has a market cap of $16.27 billion, a P/E ratio of 70.31, a P/E/G ratio of 4.47 and a beta of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. During the same period last year, the company posted $0.38 EPS. Insulet’s revenue for the quarter was up 23.2% on a year-over-year basis. On average, analysts forecast that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PODD shares. Canaccord Genuity Group lifted their price target on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler boosted their target price on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. BTIG Research cut their price target on Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Barclays lifted their price objective on Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Finally, UBS Group upped their price objective on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $231.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.